Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 06/22 | 06/22 | 1,587 sh2 trades | $80.95avg. | $128,471.73 | −9.4% | |
Paul T. QuinlanGeneral Counsel | Oruka TherapeuticsORKA | Open-market sale | 06/15 | 06/15 | 733 sh | $69.69 | $51,082.77 | −2.3% |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 06/15 | 06/15 | 7,947 sh4 trades | $69.28avg. | $550,594.99 | −19.5% | |
Oruka TherapeuticsORKA | Open-market sale | 06/15 | 06/15 | 1,729 sh | $69.69 | $120,494.01 | −0.2% | |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 06/12–06/15 | 06/15 | 9,854 sh4 trades | $69.72avg. | $687,029.01 | −36.8% | |
Oruka TherapeuticsORKA | Open-market sale | 06/15 | 06/15 | 600 sh | $69.69 | $41,814 | −0.3% | |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 06/11–06/12 | 06/12 | 35,000 sh2 trades | $70.12avg. | $2,454,298.34 | −47.5% | |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 05/21 | 05/22 | 105,000 sh3 trades | $58.97avg. | $6,191,341.39 | −58.7% | |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 05/18 | 05/18 | 10,290 sh4 trades | $59.07avg. | $607,802.6 | −38.5% | |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 05/15 | 05/15 | 7,000 sh3 trades | $61.85avg. | $432,922 | −17.3% | |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 05/01 | 05/01 | 5,000 sh6 trades | $63.88avg. | $319,380 | −2.1% | |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 04/15 | 04/15 | 7,000 sh3 trades | $66.12avg. | $462,821.59 | −17.3% | |
Paul T. QuinlanGeneral Counsel | Oruka TherapeuticsORKA | Open-market sale | 03/16 | 03/17 | 733 sh | $41.30 | $30,272.9 | −2.3% |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 03/16 | 03/17 | 7,641 sh4 trades | $40.91avg. | $312,560.39 | −18.6% | |
Oruka TherapeuticsORKA | Open-market sale | 03/16 | 03/17 | 1,729 sh | $41.30 | $71,407.7 | −0.2% | |
Arjun AgarwalSVP, Finance | Oruka TherapeuticsORKA | Open-market sale | 03/16 | 03/17 | 395 sh | $41.30 | $16,313.5 | −2.1% |
Oruka TherapeuticsORKA | Open-market sale | 03/16 | 03/17 | 600 sh | $41.30 | $24,780 | −0.3% | |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 03/02 | 03/02 | 5,000 sh2 trades | $33.56avg. | $167,817.75 | −2.1% | |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 02/17 | 02/17 | 7,000 sh2 trades | $32.36avg. | $226,549.28 | −17.1% | |
Oruka TherapeuticsORKA | Open-market sale10b5-1 plan | 01/15 | 01/16 | 7,000 sh2 trades | $31.81avg. | $222,700.92 | −82.2% |